07:00 , Aug 1, 2011 |  BC Week In Review  |  Clinical News

Adamis, Colby preclinical data

In mouse models of androgen-dependent prostate cancer and castration resistant prostate cancer (CRPC), APC-300 reduced tumor growth and prostate-specific antigen ( KLK3 ; PSA). APC-300 also decreased the growth of prostate cancer cells, inhibited androgen...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Clinical News

Adamis, Colby preclinical data

In a mouse model of pancreatic cancer, APC-300 significantly reduced tumor growth vs. controls (p<0.01). Furthermore, in human pancreatic adenocarcinoma cells, APC-300 significantly reduced the expression of the Ras oncoprotein and modulated the expression of...
08:00 , Mar 8, 2010 |  BC Week In Review  |  Company News

Adamis, Colby, La Jolla Pharmaceutical deal

Adamis received exclusive rights to Colby's CPC-300 , a small molecule signal transduction inhibitor in preclinical testing to treat prostate cancer. Colby received 1 million shares of Adamis, which are valued at $410,000 based on...